Trevena, Inc. TRVN will provide updates on its pipeline products when it releases its third-quarter 2020 results.
The company has a mixed track record, delivering an earnings beat in two of the trailing four quarters, missing in one and meeting estimates in the remaining quarter. The average earnings surprise was 3.57%. In the last reported quarter, Trevena’s earnings surprise was 0.00%.
Shares of the company have skyrocketed 216.3% in the year so far against the industry’s decline of 1.9%.
Let’s see how things are shaping up for the quarter to be reported.
Factors at Play
As Trevena has no marketed product in its portfolio, it does not generate any revenues. The company will thus provide updates on its pipeline products in the third-quarter 2020 earnings call.
In August 2020, the FDA approved Olinvyk in adults for the management of acute pain severe enough to require an intravenous opioid analgesic and for whom alternative treatments are inadequate. The company will provide updates on the launch of the drug during the third quarter.
With the approval, the company received a $3-million milestone payment from its partner in China for the U.S. approval of Olinvyk. Nhwa holds an exclusive license agreement to develop, manufacture and commercialize Olinvyk in China. The company will supportNhwa as they continue to advance Olinvyk toward regulatory approval in China. The company expects to receive future milestone payments as well as a 10% royalty on net sales of Olinvyk in China. The company is expected to provide an update on this when it releasesthird-quarter results.
The research and development expenses and the selling,general and administrative expenses are likely to have increased in the third quarter due to expenditures on the activities to support the development of TRV027 and the launch of Olinvyk.
In August 2020, the Imperial College London (ICL) initiated a proof-of-concept study on TRV027 in COVID-19 patients. Through an ongoing collaboration with ICL, Trevenais evaluating the potential of TRV027 to treat acute lung damage/abnormal blood clotting associated with COVID-19. We expect updates on the study by the company when it reports its third-quarter 2020 results.
What the Zacks Model Unveils
Our proven model does not conclusively predict an earnings beat for Trevena this season. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. But that is not the case here as you will see below.
Earnings ESP: Trevena has an Earnings ESP of 0.00%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: The company carries a Zacks Rank #2. You can see the complete list of today’s Zacks #1 Rank stocks here.
Stocks That Warrant a Look
Here are some biotech stocks with the right mix of elements to beat on earnings this time around:
Alkermes Plc. ALKS has an Earnings ESP of +142.86% and a Zacks Rank #3.
Alnylam ALNY has an Earnings ESP of +4.23% and a Zacks Rank #3.
Alexion Pharmaceuticals Inc. ALXN has an Earnings ESP of +0.84% and a Zacks Rank of 3.
Trevena, Inc. Price and EPS Surprise
Trevena, Inc. price-eps-surprise | Trevena, Inc. Quote
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market. Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2021.
Click here for the 6 trades >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Alkermes plc (ALKS) : Free Stock Analysis Report
Alexion Pharmaceuticals, Inc. (ALXN) : Free Stock Analysis Report
Alnylam Pharmaceuticals, Inc. (ALNY) : Free Stock Analysis Report
Trevena, Inc. (TRVN) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research